NHL
MCID: LYM143
MIFTS: 74

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 57 28 5 36 38
Non-Hodgkin Lymphoma 57 11 58 75 28 5 14
Lymphoma, Non-Hodgkin 57 12 43 71
Nhl 57 58 73
Lymphoma, Non-Hodgkin, Somatic 57
Lymphoma, Follicular, Somatic 57
Familial Non-Hodgkin Lymphoma 73
Follicular Lymphoma, Somatic 5
Lymphoma Non-Hodgkins 53
Non-Hodgkins Lymphoma 16
Lymphosarcoma 14

Characteristics:


Prevelance:

Non-Hodgkin Lymphoma: 1-5/10000 (Europe) 58

Age Of Onset:

Non-Hodgkin Lymphoma: Adolescent,Adult,Childhood,Elderly,Infancy 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0060060
OMIM® 57 605027
MeSH 43 D008228
ICD10 31 C85.7 C85.9
MESH via Orphanet 44 D008228
UMLS via Orphanet 72 C0024305
Orphanet 58 ORPHA547
UMLS 71 C0024305

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot: 73 Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary: Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma and follicular lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dacarbazine and Morphine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are lymphoma and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology: 11 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Orphanet: 58 A heterogeneous group of malignant tumors of the lymphoid system.

Wikipedia: 75 Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that... more...

More information from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1253)
# Related Disease Score Top Affiliating Genes
1 lymphoma 34.6 TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
2 follicular lymphoma 34.1 TP53 PIK3CA MYC IRF4 EZH2 BCL6
3 mantle cell lymphoma 34.0 TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
4 lymphoma, hodgkin, classic 34.0 TP53 TNFRSF8 IRF4 BCL6 BCL2
5 b-cell lymphoma 33.9 TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
6 leukemia, chronic lymphocytic 33.9 TP53 TNFRSF8 PRF1 NRAS MYD88 MYC
7 burkitt lymphoma 33.9 TP53 TNFRSF8 MYC IRF4 BCL6 BCL2
8 diffuse large b-cell lymphoma 33.8 TNFRSF8 MYD88 MYC IRF4 EZH2 BCL6
9 lymphoma, mucosa-associated lymphoid type 33.7 TP53 TNFRSF8 MYD88 MYC IRF4 BCL6
10 angioimmunoblastic t-cell lymphoma 33.2 TNFRSF8 RHOA IRF4 BCL6
11 plasmablastic lymphoma 33.2 TNFRSF8 MYC IRF4 BCL6
12 gastric lymphoma 33.2 TNFRSF8 IRF4 BCL6 BCL2 BCL10
13 mature t-cell and nk-cell lymphoma 33.1 TP53 TNFRSF8 MYC BCL6 BCL2
14 composite lymphoma 33.1 TNFRSF8 BCL6 BCL2
15 high-grade b-cell lymphoma double-hit/triple-hit 33.0 MYC IRF4 EZH2 BCL6 BCL2
16 common variable immunodeficiency 32.8 TP53 TNFRSF8 IRF4 BCL2
17 marginal zone b-cell lymphoma 32.7 TNFRSF8 MYD88 MYC IRF4 BCL6 BCL2
18 primary cutaneous gamma-delta t-cell lymphoma 32.7 TNFRSF8 PRF1
19 myeloma, multiple 32.7 TP53 TNFRSF8 PIK3CA NRAS MYD88 MYC
20 leukemia, acute myeloid 32.6 TP53 TNFRSF8 PRF1 PIK3CA NRAS MYC
21 leukemia 32.5 TP53 NRAS MYC BRAF BCL2 BCL10
22 acquired immunodeficiency syndrome 32.5 TP53 MYC BCL6 BCL2 B2M
23 lymphoproliferative syndrome 32.4 TNFRSF8 PRF1 NRAS CASP10 BCL6 BCL2
24 leukemia, acute lymphoblastic 32.4 TP53 MYC IRF4 BCL6 BCL2
25 chronic lymphocytic leukemia/small lymphocytic lymphoma 32.3 TP53 TNFRSF8 BCL6 BCL2
26 primary mediastinal b-cell lymphoma 32.3 TNFRSF8 MYC IRF4 BCL6 BCL2
27 lymphoblastic lymphoma 32.2 TNFRSF8 BCL6 BCL2
28 peripheral t-cell lymphoma 32.2 TP53 TNFRSF8 BCL6 BCL2
29 reticulosarcoma 32.2 TNFRSF8 MYC BCL6 BCL2 B2M
30 central nervous system lymphoma 32.1 TNFRSF8 MYD88 MYC IRF4 BCL6 BCL2
31 lymphoplasmacytic lymphoma 32.1 MYD88 IRF4 BCL6 BCL2 B2M
32 renal cell carcinoma, nonpapillary 32.1 TP53 RHOA PIK3CA NRAS MYC MAP2K1
33 peripheral nervous system disease 32.1 TP53 TNFRSF8 RHOA NRAS MYC MAP2K1
34 waldenstroem's macroglobulinemia 32.0 MYD88 IRF4 B2M
35 breast lymphoma 32.0 TNFRSF8 IRF4 BCL6 BCL2
36 t-cell acute lymphoblastic leukemia 32.0 TNFRSF8 MYC IRF4 BCL2 BCL10
37 myelodysplastic syndrome 32.0 TP53 NRAS MYC EZH2 BCL2
38 bone lymphoma 32.0 TNFRSF8 IRF4 BCL6 BCL2
39 hepatitis b 32.0 PIK3CA MYD88 MYC BCL2
40 adult t-cell leukemia/lymphoma 32.0 TP53 TNFRSF8 MYC IRF4 BCL2
41 macroglobulinemia 31.9 TP53 MYD88 BCL2
42 lymphatic system disease 31.9 TP53 TNFRSF8 MYC IRF4 BCL6 BCL2
43 skin melanoma 31.9 TP53 PIK3CA NRAS MYC MAP2K1 EZH2
44 leukemia, chronic myeloid 31.9 TP53 NRAS MYC IRF4 BRAF BCL2
45 gastric cancer 31.8 TP53 RHOA PIK3CA NRAS MYC MAP2K1
46 melanoma 31.8 TP53 RHOA PIK3CA NRAS MYC MAP2K1
47 lymphoma aids related 31.8 MYC BCL6
48 pancreatic cancer 31.8 TP53 RHOA PRF1 PIK3CA MYC MAP2K1
49 testicular lymphoma 31.8 TNFRSF8 MYD88 IRF4 BCL6 BCL2
50 skin carcinoma 31.8 TP53 NRAS MYC BCL2

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphoma 30 HP:0002665

Clinical features from OMIM®:

605027 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.74 BCL10 MYD88 RAD54L
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.74 BCL10 MYD88 RAD54B RAD54L RHOA TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.74 RAD54B RAD54L TP53

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 B2M BCL2 BCL6 BRAF EZH2 IRF4
2 endocrine/exocrine gland MP:0005379 10.37 B2M BCL10 BCL2 BCL6 BRAF EZH2
3 neoplasm MP:0002006 10.36 B2M BCL2 BRAF EZH2 IRF4 MAP2K1
4 growth/size/body region MP:0005378 10.36 B2M BCL2 BCL6 BRAF EZH2 IRF4
5 nervous system MP:0003631 10.34 B2M BCL10 BCL2 BRAF EZH2 MAP2K1
6 cellular MP:0005384 10.33 B2M BCL10 BCL2 BCL6 BRAF EZH2
7 normal MP:0002873 10.23 BCL6 BRAF EZH2 MAP2K1 MYC NRAS
8 immune system MP:0005387 10.22 B2M BCL10 BCL2 BCL6 BRAF EZH2
9 embryo MP:0005380 10.18 BCL10 BCL2 BRAF EZH2 MAP2K1 MYC
10 digestive/alimentary MP:0005381 10.16 B2M BCL2 BRAF EZH2 MAP2K1 MYC
11 liver/biliary system MP:0005370 10.15 B2M BCL6 BRAF MYC MYD88 NRAS
12 adipose tissue MP:0005375 10.14 BCL2 BCL6 BRAF IRF4 MYC MYD88
13 no phenotypic analysis MP:0003012 10.11 BCL6 EZH2 MYC MYD88 NRAS PIK3CA
14 cardiovascular system MP:0005385 10.11 B2M BCL2 BCL6 BRAF EZH2 MAP2K1
15 hematopoietic system MP:0005397 10.06 B2M BCL10 BCL2 BCL6 BRAF EZH2
16 reproductive system MP:0005389 10 B2M BCL2 BCL6 BRAF EZH2 MAP2K1
17 craniofacial MP:0005382 9.98 BCL2 BRAF EZH2 MAP2K1 MYC NRAS
18 mortality/aging MP:0010768 9.86 B2M BCL10 BCL2 BCL6 BRAF EZH2
19 integument MP:0010771 9.4 B2M BCL2 BCL6 BRAF EZH2 MAP2K1

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4 4342-03-4 2942 5351166
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
6
Plerixafor Approved Phase 4 110078-46-1 65015
7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
8
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Nitric Oxide Approved Phase 4 10102-43-9 145068
11
Prilocaine Approved Phase 4 721-50-6 4906
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Pirarubicin Investigational Phase 4 72496-41-4 4844
14
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
15
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
16 Antifungal Agents Phase 4
17 Anti-Retroviral Agents Phase 4
18 Anti-HIV Agents Phase 4
19 Anti-Arrhythmia Agents Phase 4
20 Angiotensin Receptor Antagonists Phase 4
21 Angiotensin II Type 1 Receptor Blockers Phase 4
22 Giapreza Phase 4
23 Lidocaine, Prilocaine Drug Combination Phase 4
24 Sodium Channel Blockers Phase 4
25 Anesthetics, Inhalation Phase 4
26 Anesthetics, General Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
29
Epoetin Alfa Phase 4
30 Hematinics Phase 4
31 Chrysarobin Phase 4
32
Aldesleukin Approved Phase 3 110942-02-4
33
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
34
Allopurinol Approved Phase 3 315-30-0 2094 135401907
35
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
36
Histamine Approved, Investigational Phase 3 51-45-6 774
37
Acetaminophen Approved Phase 3 103-90-2 1983
38
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
39
Promethazine Approved, Investigational Phase 3 60-87-7 4927
40
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
41
Zoledronic acid Approved Phase 3 118072-93-8 68740
42
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
43
Rasburicase Approved, Investigational Phase 3 134774-45-1
44
Calcium carbonate Approved, Investigational Phase 3 471-34-1
45
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 11947679 6857599
46
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
47
Famotidine Approved Phase 3 76824-35-6 3325 5702160
48
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
49
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
50
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032

Interventional clinical trials:

(show top 50) (show all 2064)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Unknown status NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
3 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Unknown status NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
5 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
6 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
7 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
8 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
9 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
10 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
11 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;EMLA
12 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
13 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
14 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
15 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
16 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
17 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
18 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
19 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
20 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
21 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus
22 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) Recruiting NCT05518383 Phase 4 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
23 Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte Recruiting NCT04460235 Phase 4 Prevenar13 Pneumo-23
24 Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study - Intervention Pilot Study Recruiting NCT05191225 Phase 4 RiTUXimab Injection [Truxima]
25 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
26 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
27 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
28 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
29 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
30 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
31 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Unknown status NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
32 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
33 Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
34 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
35 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
36 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
37 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab
38 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
39 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
40 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
42 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
43 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
44 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
45 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
46 Non-Hodgkin's Lymphoma T Cell Protocol Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
47 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
48 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Unknown status NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
49 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
50 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bendamustine
Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cladribine
fludarabine
Fludarabine phosphate
Ifosfamide
Lomustine
mercaptopurine
pegaspargase
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, non-hodgkin

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 28
2 Lymphoma, Non-Hodgkin, Familial 28 BCL10 CASP10 PRF1 RAD54B RAD54L

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

Organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

MalaCards : T Cells, Bone Marrow, Bone, B Cells, Nk Cells, Breast, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 17731)
# Title Authors PMID Year
1
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. 53 62 5
12010812 2002
2
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. 62 57
21796119 2011
3
Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. 62 57
15811955 2005
4
A proportion of patients with lymphoma may harbor mutations of the perforin gene. 62 57
15728124 2005
5
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
6
A tumour suppressor network relying on the polyamine-hypusine axis. 57
22722845 2012
7
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. 57
21390126 2011
8
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 57
20081860 2010
9
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 57
20054396 2010
10
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. 57
19412164 2009
11
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 57
18323416 2008
12
BRAF mutations in non-Hodgkin's lymphoma. 5
14612909 2003
13
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 5
12960123 2003
14
Inactivating mutations of the caspase-10 gene in gastric cancer. 5
11973654 2002
15
Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. 57
10651726 2000
16
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. 5
10362364 1999
17
Mutations in the RAD54 recombination gene in primary cancers. 5
10362365 1999
18
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 5
9989495 1999
19
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. 5
1565144 1992
20
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 53 62
19965662 2010
21
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. 53 62
20038219 2010
22
An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. 53 62
19897031 2010
23
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. 53 62
19809881 2010
24
Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. 53 62
19821039 2010
25
Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. 53 62
20414345 2010
26
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. 53 62
19748593 2010
27
Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. 53 62
19751723 2009
28
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 53 62
19917125 2009
29
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 53 62
19734146 2009
30
Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. 53 62
19396635 2009
31
Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. 53 62
19811326 2009
32
[Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. 53 62
19954624 2009
33
Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. 53 62
19137297 2009
34
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. 53 62
19834627 2009
35
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. 53 62
19388933 2009
36
Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. 53 62
19452252 2009
37
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. 53 62
19383901 2009
38
BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. 53 62
19258594 2009
39
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 53 62
19245433 2009
40
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. 53 62
19225536 2009
41
Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. 53 62
19100628 2009
42
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. 53 62
18981293 2009
43
Targeting CD40 in Waldenström's macroglobulinemia. 53 62
19362983 2009
44
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. 53 62
19135941 2009
45
Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. 53 62
18776814 2008
46
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. 53 62
18940680 2008
47
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. 53 62
18546271 2008
48
Primary tracheal lymphoma causing respiratory failure. 53 62
18670314 2008
49
Serum CA125 and PSA concentrations in patients with lymphoma. 53 62
18654120 2008
50
Polymorphisms of human N-acetyltransferases and cancer risk. 53 62
18680472 2008

Variations for Lymphoma, Non-Hodgkin, Familial

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

5 (show top 50) (show all 67)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RAD54L NM_003579.4(RAD54L):c.1331T>A (p.Val444Glu) SNV Pathogenic
6192 rs121908689 GRCh37: 1:46738430-46738430
GRCh38: 1:46272758-46272758
2 BCL10 NM_003921.5(BCL10):c.427_428dup (p.Glu145fs) DUP Pathogenic
6253 rs587776632 GRCh37: 1:85733583-85733584
GRCh38: 1:85267900-85267901
3 BCL10 NM_003921.5(BCL10):c.231dup (p.Gly78fs) DUP Pathogenic
6254 rs587776633 GRCh37: 1:85736415-85736416
GRCh38: 1:85270732-85270733
4 BCL10 NM_003921.5(BCL10):c.525_541del (p.Val176fs) DEL Pathogenic
6255 rs587776634 GRCh37: 1:85733471-85733487
GRCh38: 1:85267788-85267804
5 BCL10 NM_003921.5(BCL10):c.410del (p.Asn137fs) DEL Pathogenic
6256 rs587776635 GRCh37: 1:85733602-85733602
GRCh38: 1:85267919-85267919
6 BCL10 NM_003921.5(BCL10):c.398dup (p.Ser134fs) DUP Pathogenic
6257 rs587776636 GRCh37: 1:85733613-85733614
GRCh38: 1:85267930-85267931
7 BCL10 NM_003921.5(BCL10):c.629AAG[2] (p.Glu212del) MICROSAT Pathogenic
6258 rs587776637 GRCh37: 1:85733375-85733377
GRCh38: 1:85267692-85267694
8 CASP10 NM_032977.4(CASP10):c.1241C>T (p.Ala414Val) SNV Pathogenic
7765 rs28936699 GRCh37: 2:202074111-202074111
GRCh38: 2:201209388-201209388
9 CASP10 NM_032977.4(CASP10):c.769C>T (p.Gln257Ter) SNV Pathogenic
7766 rs121909775 GRCh37: 2:202070652-202070652
GRCh38: 2:201205929-201205929
10 CASP10 NM_032977.4(CASP10):c.1042_1043insA (p.Gly348fs) INSERT Pathogenic
7767 rs398122800 GRCh37: 2:202073912-202073913
GRCh38: 2:201209189-201209190
11 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg) SNV Pathogenic
13970 rs121913357 GRCh37: 7:140481403-140481403
GRCh38: 7:140781603-140781603
12 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) SNV Pathogenic
13971 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
13 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) SNV Pathogenic
13972 rs121913338 GRCh37: 7:140453154-140453154
GRCh38: 7:140753354-140753354
14 RAD54B NM_012415.3(RAD54B):c.1778A>G (p.Asn593Ser) SNV Pathogenic
5638 rs114216685 GRCh37: 8:95403868-95403868
GRCh38: 8:94391640-94391640
15 B2M NM_004048.4(B2M):c.286G>A (p.Asp96Asn) SNV Pathogenic
31907 rs398122820 GRCh37: 15:45007839-45007839
GRCh38: 15:44715641-44715641
16 TP53 NM_000546.6(TP53):c.974G>T (p.Gly325Val) SNV Pathogenic
12367 rs121912659 GRCh37: 17:7576872-7576872
GRCh38: 17:7673554-7673554
17 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
18 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely Pathogenic
376659 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
19 TP53 NM_000546.6(TP53):c.722C>T (p.Ser241Phe) SNV Likely Pathogenic
12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
20 TP53 NM_000546.6(TP53):c.844C>G (p.Arg282Gly) SNV Likely Pathogenic
140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
21 TP53 NM_000546.6(TP53):c.721T>G (p.Ser241Ala) SNV Likely Pathogenic
376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
22 TP53 NM_000546.6(TP53):c.614A>G (p.Tyr205Cys) SNV Likely Pathogenic
376681 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
23 TP53 NM_000546.6(TP53):c.613T>C (p.Tyr205His) SNV Likely Pathogenic
376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
24 TP53 NM_000546.6(TP53):c.845G>A (p.Arg282Gln) SNV Likely Pathogenic
237956 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
25 TP53 NM_000546.6(TP53):c.613T>A (p.Tyr205Asn) SNV Likely Pathogenic
376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
26 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely Pathogenic
177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
27 TP53 NM_000546.6(TP53):c.721T>C (p.Ser241Pro) SNV Likely Pathogenic
376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
28 TP53 NM_000546.6(TP53):c.614A>T (p.Tyr205Phe) SNV Likely Pathogenic
376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
29 TP53 NM_000546.6(TP53):c.613T>G (p.Tyr205Asp) SNV Likely Pathogenic
376686 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
30 TP53 NM_000546.6(TP53):c.722C>A (p.Ser241Tyr) SNV Likely Pathogenic
376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
31 TP53 NM_000546.6(TP53):c.614A>C (p.Tyr205Ser) SNV Likely Pathogenic
376683 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
32 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro) SNV Likely Pathogenic
37055 rs387907272 GRCh37: 3:38182641-38182641
GRCh38: 3:38141150-38141150
33 PIK3CA NM_006218.4(PIK3CA):c.1031T>G (p.Val344Gly) SNV Likely Pathogenic
376497 rs1057519941 GRCh37: 3:178921549-178921549
GRCh38: 3:179203761-179203761
34 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu) SNV Likely Pathogenic
376459 rs1057519918 GRCh37: 8:128750636-128750636
GRCh38: 8:127738390-127738390
35 RHOA NM_001664.4(RHOA):c.125A>C (p.Tyr42Ser) SNV Likely Pathogenic
376523 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
36 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile) SNV Likely Pathogenic
376300 rs756091827 GRCh37: 8:128750681-128750681
GRCh38: 8:127738435-127738435
37 MAP2K1 NM_002755.4(MAP2K1):c.171G>C (p.Lys57Asn) SNV Likely Pathogenic
376174 rs869025608 GRCh37: 15:66727455-66727455
GRCh38: 15:66435117-66435117
38 B2M NM_004048.4(B2M):c.2T>G (p.Met1Arg) SNV Likely Pathogenic
376372 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
39 RHOA NM_001664.4(RHOA):c.13C>T (p.Arg5Trp) SNV Likely Pathogenic
376519 rs1057519952 GRCh37: 3:49413010-49413010
GRCh38: 3:49375577-49375577
40 RHOA NM_001664.4(RHOA):c.14G>T (p.Arg5Leu) SNV Likely Pathogenic
376521 rs1057519953 GRCh37: 3:49413009-49413009
GRCh38: 3:49375576-49375576
41 B2M NM_004048.4(B2M):c.3G>A (p.Met1Ile) SNV Likely Pathogenic
376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
42 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro) SNV Likely Pathogenic
376458 rs750664148 GRCh37: 8:128750680-128750680
GRCh38: 8:127738434-127738434
43 B2M NM_004048.4(B2M):c.2T>C (p.Met1Thr) SNV Likely Pathogenic
376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
44 RHOA NM_001664.4(RHOA):c.125A>T (p.Tyr42Phe) SNV Likely Pathogenic
376524 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
45 B2M NM_004048.4(B2M):c.1A>G (p.Met1Val) SNV Likely Pathogenic
376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
46 B2M NM_004048.4(B2M):c.1A>T (p.Met1Leu) SNV Likely Pathogenic
376370 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
47 MAP2K1 NM_002755.4(MAP2K1):c.170A>C (p.Lys57Thr) SNV Likely Pathogenic
376448 rs1057519909 GRCh37: 15:66727454-66727454
GRCh38: 15:66435116-66435116
48 RHOA NM_001664.4(RHOA):c.125A>G (p.Tyr42Cys) SNV Likely Pathogenic
376522 rs1057519954 GRCh37: 3:49412898-49412898
GRCh38: 3:49375465-49375465
49 RHOA NM_001664.4(RHOA):c.14G>A (p.Arg5Gln) SNV Likely Pathogenic
376520 rs1057519953 GRCh37: 3:49413009-49413009
GRCh38: 3:49375576-49375576
50 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Likely Pathogenic
13899 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

73
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CNTRL Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TP53 TNFRSF8 RHOA PIK3CA NRAS MYD88
2
Show member pathways
13.88 TP53 TNFRSF8 RHOA NRAS MYC MAP2K1
3
Show member pathways
13.86 B2M BRAF EZH2 MAP2K1 MYC MYD88
4 13.81 TP53 RHOA PIK3CA NRAS MYD88 MYC
5
Show member pathways
13.76 TP53 RHOA NRAS MYC MAP2K1 BRAF
6
Show member pathways
13.69 TP53 TNFRSF8 NRAS MYC MAP2K1 CASP10
7
Show member pathways
13.6 TP53 RHOA PIK3CA NRAS MYC MAP2K1
8
Show member pathways
13.48 TP53 RHOA PIK3CA NRAS MYD88 MYC
9
Show member pathways
13.08 B2M BCL2 BCL6 IRF4 MAP2K1 MYC
10
Show member pathways
13.01 TP53 PIK3CA NRAS MYC MAP2K1 BCL2
11
Show member pathways
12.92 RHOA PIK3CA NRAS MAP2K1 BRAF
12
Show member pathways
12.92 PIK3CA NRAS MYC MAP2K1 BRAF BCL2
13
Show member pathways
12.91 RHOA PIK3CA NRAS MAP2K1 BRAF
14
Show member pathways
12.9 TP53 RHOA PRF1 PIK3CA MYC MAP2K1
15 12.89 RHOA PIK3CA NRAS MYC MAP2K1 BRAF
16
Show member pathways
12.8 BRAF MAP2K1 NRAS PIK3CA RHOA
17 12.75 TP53 PIK3CA MYC MAP2K1 EZH2 BCL2
18
Show member pathways
12.69 IRF4 MAP2K1 MYC NRAS PIK3CA TP53
19
Show member pathways
12.68 TNFRSF8 MYD88 MAP2K1 CASP10 BCL2
20
Show member pathways
12.65 BCL2 MYC NRAS PIK3CA TP53
21
Show member pathways
12.62 RHOA PIK3CA NRAS MAP2K1 BRAF
22 12.62 TNFRSF8 MYD88 IRF4 BCL6 BCL10 B2M
23
Show member pathways
12.59 TP53 RHOA PIK3CA NRAS MYC MAP2K1
24
Show member pathways
12.54 TP53 PIK3CA NRAS MYD88 MYC MAP2K1
25
Show member pathways
12.51 TP53 PIK3CA MAP2K1 BRAF BCL2
26
Show member pathways
12.5 RHOA PIK3CA NRAS MYD88 MAP2K1
27
Show member pathways
12.48 BRAF MAP2K1 MYC NRAS PIK3CA TP53
28
Show member pathways
12.47 RHOA PIK3CA NRAS MAP2K1 BCL2
29
Show member pathways
12.46 RHOA PIK3CA MAP2K1 BRAF
30 12.46 TP53 NRAS MYC MAP2K1 BRAF
31
Show member pathways
12.46 TP53 PIK3CA NRAS MAP2K1 CASP10 BCL2
32
Show member pathways
12.44 BRAF MAP2K1 NRAS PIK3CA RHOA
33
Show member pathways
12.42 TP53 MAP2K1 CASP10 BCL2
34
Show member pathways
12.41 PRF1 MYC BCL2 BCL10
35
Show member pathways
12.4 PRF1 MAP2K1 CASP10 BCL2
36
Show member pathways
12.38 RHOA PIK3CA MYC MAP2K1
37
Show member pathways
12.37 TP53 PIK3CA MYD88 MAP2K1
38
Show member pathways
12.37 PIK3CA NRAS MAP2K1 BCL6
39 12.34 BCL2 BRAF MAP2K1 PIK3CA RHOA
40
Show member pathways
12.33 RHOA PIK3CA MYC MAP2K1 BRAF
41
Show member pathways
12.32 TP53 PIK3CA MYC MAP2K1
42 12.3 MAP2K1 NRAS PIK3CA RHOA
43
Show member pathways
12.26 PIK3CA NRAS MAP2K1 BCL2
44 12.25 TP53 MYC MAP2K1 BRAF
45 12.24 TP53 PIK3CA MAP2K1 EZH2
46
Show member pathways
12.2 BCL10 MAP2K1 MYD88 PIK3CA TP53
47
Show member pathways
12.19 RHOA NRAS MAP2K1 BRAF
48 12.19 RHOA PIK3CA NRAS MAP2K1 BRAF
49
Show member pathways
12.19 TP53 RHOA NRAS MYC MAP2K1 BRAF
50
Show member pathways
12.19 TP53 PIK3CA NRAS MYC MAP2K1 BRAF

GO Terms for Lymphoma, Non-Hodgkin, Familial

Cellular components related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.44 TP53 RAD54L MYD88 MYC CASP10 BCL2

Biological processes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.27 TP53 TNFRSF8 BCL6 BCL2 BCL10
2 cellular response to DNA damage stimulus GO:0006974 10.18 TP53 RAD54L RAD54B MYC BCL6 BCL2
3 MAPK cascade GO:0000165 10.13 BRAF MAP2K1 MYC NRAS
4 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 10.04 RHOA MYC BCL10
5 thymus development GO:0048538 10.01 MAP2K1 BRAF BCL2
6 chromosome organization GO:0051276 9.93 TP53 RAD54L MYC
7 regulation of gene expression GO:0010468 9.92 PIK3CA MYD88 MYC FAS-AS1 EZH2 BCL2
8 response to gamma radiation GO:0010332 9.91 BCL2 MYC TP53
9 response to amino acid GO:0043200 9.88 RHOA MYD88 BCL2
10 determination of adult lifespan GO:0008340 9.85 TP53 RAD54L RAD54B
11 B cell lineage commitment GO:0002326 9.8 TP53 BCL2
12 regulation of cell population proliferation GO:0042127 9.8 BCL6 BRAF EZH2 MYD88 TP53
13 regulation of axon regeneration GO:0048679 9.72 MAP2K1 BRAF
14 positive regulation of protein serine/threonine kinase activity GO:0071902 9.7 RHOA PIK3CA MAP2K1 EZH2
15 response to xenobiotic stimulus GO:0009410 9.7 TP53 RHOA RAD54L RAD54B MYC BCL2
16 T cell lineage commitment GO:0002360 9.69 TP53 BCL2
17 positive regulation of miRNA maturation GO:1903800 9.56 TP53 MAP2K1
18 T cell differentiation in thymus GO:0033077 9.23 TP53 BRAF BCL2 B2M

Molecular functions related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP-dependent DNA/DNA annealing activity GO:0036310 9.26 TP53 RAD54L
2 DNA translocase activity GO:0015616 8.92 RAD54L RAD54B

Sources for Lymphoma, Non-Hodgkin, Familial

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....